Get the Stockscreener App
22.35
3.08%
-0.71
After Hours:
22.41
0.06
+0.27%
Pacira Biosciences Inc stock is traded at $22.35, with a volume of 432.29K.
It is down -3.08% in the last 24 hours and down -16.01% over the past month.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
See More
Previous Close:
$23.06
Open:
$23.06
24h Volume:
432.29K
Relative Volume:
0.68
Market Cap:
$1.00B
Revenue:
$681.75M
Net Income/Loss:
$70.47M
P/E Ratio:
15.41
EPS:
1.45
Net Cash Flow:
$173.19M
1W Performance:
-10.02%
1M Performance:
-16.01%
6M Performance:
-5.66%
1Y Performance:
+44.10%
1-Day Range:
$22.30
$23.06
1-Week Range:
$22.30
$25.30
52-Week Range:
$15.50
$27.98
Pacira Biosciences Inc Stock (PCRX) Company Profile
Name
Pacira Biosciences Inc
Sector
Phone
650-242-8052
Address
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Compare PCRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
22.35 | 1.04B | 681.75M | 70.47M | 173.19M | 1.45 |
|
ZTS
Zoetis Inc
|
141.11 | 63.55B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.71 | 44.47B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.00 | 40.17B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.03 | 22.99B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
440.00 | 20.14B | 3.08B | 1.24B | 1.07B | 25.61 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-25 | Upgrade | Truist | Hold → Buy |
| Jan-30-25 | Upgrade | Truist | Sell → Hold |
| Aug-13-24 | Downgrade | Truist | Buy → Sell |
| Aug-12-24 | Downgrade | JP Morgan | Overweight → Underweight |
| Aug-12-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-12-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-03-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-07-24 | Resumed | JP Morgan | Overweight |
| Dec-20-23 | Initiated | Raymond James | Outperform |
| Aug-03-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Jan-31-23 | Resumed | Wedbush | Outperform |
| Oct-21-22 | Resumed | Jefferies | Buy |
| Jan-03-22 | Resumed | JP Morgan | Overweight |
| Jul-26-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-21-21 | Resumed | JP Morgan | Neutral |
| Apr-09-21 | Initiated | Berenberg | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-11-21 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jan-21-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jul-06-20 | Reiterated | Needham | Buy |
| May-27-20 | Initiated | Guggenheim | Neutral |
| Apr-07-20 | Initiated | Northland Capital | Outperform |
| Mar-20-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-24-20 | Initiated | SunTrust | Buy |
| Jan-23-20 | Initiated | SunTrust | Buy |
| Nov-06-19 | Initiated | BTIG Research | Buy |
| Jun-11-19 | Initiated | Barclays | Overweight |
| May-06-19 | Upgrade | Mizuho | Underperform → Neutral |
| May-02-19 | Upgrade | Stifel | Sell → Hold |
| Feb-01-19 | Downgrade | Mizuho | Neutral → Underperform |
| Aug-06-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Apr-09-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-21-18 | Reiterated | Mizuho | Neutral |
| Feb-16-18 | Downgrade | Needham | Buy → Hold |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
| Jan-04-18 | Reiterated | Canaccord Genuity | Buy |
| Jan-03-18 | Initiated | Leerink Partners | Mkt Perform |
View All
Pacira Biosciences Inc Stock (PCRX) Latest News
How Pacira BioSciences Inc. (82P) stock behaves under inflation pressureWeekly Earnings Recap & Low Risk High Reward Ideas - newser.com
Pacira BioSciences (NASDAQ:PCRX) Given "Sell (D)" Rating at Weiss Ratings - MarketBeat
How to interpret RSI for Pacira BioSciences Inc. stock2025 Big Picture & Advanced Swing Trade Entry Plans - newser.com
Detecting support and resistance levels for Pacira BioSciences Inc.July 2025 Sector Moves & Fast Entry and Exit Trade Plans - newser.com
Will Pacira BioSciences Inc. (82P) stock split increase liquidityEarnings Performance Report & Stepwise Entry and Exit Trade Signals - newser.com
Pacira BioSciences Inc. stock trend outlook and recovery path2025 Major Catalysts & Weekly Chart Analysis and Trade Guides - newser.com
What moving averages say about Pacira BioSciences Inc.Weekly Trend Report & Weekly Top Gainers Alerts - newser.com
Pacira BioSciences Inc. stock volume spike explained2025 Price Targets & Fast Entry High Yield Stock Tips - newser.com
What momentum shifts mean for Pacira BioSciences Inc.Inflation Watch & Consistent Return Investment Signals - newser.com
Custom watchlist performance reports with Pacira BioSciences Inc.2025 Stock Rankings & Growth Oriented Trading Recommendations - newser.com
Pacira BioSciences Becomes Oversold (PCRX) - Nasdaq
Pacira BioSciences, Inc. $PCRX Shares Bought by Gagnon Securities LLC - MarketBeat
Gagnon Advisors LLC Has $5.10 Million Position in Pacira BioSciences, Inc. $PCRX - MarketBeat
Robeco Institutional Asset Management B.V. Has $1.29 Million Holdings in Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira Biosciences, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Possible Bearish Signals With Pacira BioSciences Insiders Disposing Stock - simplywall.st
Raymond James Maintains Pacira BioSciences(PCRX.US) With Hold Rating - 富途牛牛
Applying Elliott Wave Theory to Pacira BioSciences Inc.Fed Meeting & Smart Money Movement Alerts - newser.com
Long term hold vs stop loss in Pacira BioSciences Inc.July 2025 Macro Moves & Stepwise Trade Signal Implementation - newser.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Stockholders to Connect - ACCESS Newswire
Will Pacira BioSciences Inc. stock gain from government policiesWeekly Risk Report & Capital Efficiency Focused Strategies - newser.com
Using Bollinger Bands to evaluate Pacira BioSciences Inc.Chart Signals & Entry Point Confirmation Alerts - newser.com
Can Pacira BioSciences Inc. (82P) stock hold up in economic slowdownPrice Action & Daily Stock Momentum Reports - newser.com
Greenwood Capital Associates LLC Takes $314,000 Position in Pacira BioSciences, Inc. $PCRX - MarketBeat
Why Institutions Believe Medinova Diagnostic Services Limited Is Undervalued TodayDividend Aristocrats List & Free Unlock Portfolio Growth - earlytimes.in
What drives Pacira BioSciences Inc stock priceLarge Cap Stability Picks & Today’s Picks, Tomorrow’s Winners - earlytimes.in
Pacira Biosciences (PCRX) Grants Inducement Awards to New Employ - GuruFocus
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Pacira BioSciences reports inducement grants - MarketScreener
50,600 Shares: Pacira Grants Inducement Awards to 15 New Employees; $24.58 Exercise Price - Stock Titan
Why Pacira BioSciences Inc. (82P) stock could outperform next yearPortfolio Performance Summary & Growth Focused Investment Plans - newser.com
Farther Finance Advisors LLC Boosts Holdings in Pacira BioSciences, Inc. $PCRX - Defense World
Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Is Ganga Forging Limited Still a Good Stock to Buy After Recent EarningsSupport Zone Identification & Big Profit Small Budget - earlytimes.in
Pacira Biosciences Inc Stock (PCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
1.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):